Antibody Information
General Information of This Antibody
| Antibody ID | ANI0ZADON |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-5T4 scFv-Fc antibody |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa/(scFv-Fc-kappa) |
|||||
| Antigen Name | Trophoblast glycoprotein (TPBG) |
Antigen Info | ||||
The Activity Data of This Antibody
| Antibody Activity Information 1 | [1] | |||||
|
Dissociation Constant (Kd)
|
<30 |
pM
|
||||
|---|---|---|---|---|---|---|
| Antibody Function | Confirm the effect of the drug conjugation with the anti-5T4 Ab and ASN-004 on binding activity to target. | |||||
| Antibody Antigen Binding Assay | Binding kinetics and affinity to human 5T4 extracellular domain antigen protein were determined by surface plasmon resonance (SPR, BIAcore). | |||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
ASN-004 [Phase 1]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 28.20% (Day 21) | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 0.3 mg/kg single dose.
Click to Show/Hide
|
||||
| In Vivo Model | Cervical cancer CDX model | ||||
| In Vitro Model | Skin squamous cell carcinoma | A431 cells | CVCL_0037 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 54.30% (Day 60) | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was further evaluated in a tumor xenograft model derived from the H1975 human lung carcinoma cell line [5T4+; 15, 800 binding sites per cell]. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 0.3 mg/kg Q4D 4.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer CDX model | ||||
| In Vitro Model | Lung cancer | Lung cancer cells | Homo sapiens | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 55.50% (Day 12) | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 1 mg/kg Q4D 4.
|
||||
| In Vivo Model | Cervical advanced-stage cancer CDX model | ||||
| In Vitro Model | Cervical advanced-stage cancer | Cervical advanced-stage cancer cells | Homo sapiens | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.20% (Day 21) | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 1 mg/kg single dose.
Click to Show/Hide
|
||||
| In Vivo Model | Cervical cancer CDX model | ||||
| In Vitro Model | Skin squamous cell carcinoma | A431 cells | CVCL_0037 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 96.30% (Day 21) | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 3 mg/kg single dose.
Click to Show/Hide
|
||||
| In Vivo Model | Cervical cancer CDX model | ||||
| In Vitro Model | Skin squamous cell carcinoma | A431 cells | CVCL_0037 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 40) | Negative 5T4 expression (5T4-) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. A tumor xenograft model derived from the NCI-N87 human gastric tumor cell line [5T4-; 4, 400 binding sites per cell] and high expression of HER2. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 3 mg/kg single dose.
Click to Show/Hide
|
||||
| In Vivo Model | Gastric cancer CDX model | ||||
| In Vitro Model | Gastric cancer | Gastric cancer cells | Homo sapiens | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 40) | Negative 5T4 expression (5T4-) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. A tumor xenograft model derived from the NCI-N87 human gastric tumor cell line [5T4-; 4, 400 binding sites per cell] and high expression of HER2. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 3 mg/kg Q4D 3.
Click to Show/Hide
|
||||
| In Vivo Model | Gastric cancer CDX model | ||||
| In Vitro Model | Gastric cancer | Gastric cancer cells | Homo sapiens | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 60) | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was further evaluated in a tumor xenograft model derived from the H1975 human lung carcinoma cell line [5T4+; 15, 800 binding sites per cell]. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 1 mg/kg Q4D 4.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer CDX model | ||||
| In Vitro Model | Lung cancer | Lung cancer cells | Homo sapiens | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 60) | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was further evaluated in a tumor xenograft model derived from the H1975 human lung carcinoma cell line [5T4+; 15, 800 binding sites per cell]. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 3 mg/kg Q4D 4.
Click to Show/Hide
|
||||
| In Vivo Model | Lung cancer CDX model | ||||
| In Vitro Model | Lung cancer | Lung cancer cells | Homo sapiens | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 40) | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 1 mg/kg Q4D 4.
Click to Show/Hide
|
||||
| In Vivo Model | Cervical cancer CDX model | ||||
| In Vitro Model | Skin squamous cell carcinoma | A431 cells | CVCL_0037 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 40) | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 3 mg/kg Q4D 4.
Click to Show/Hide
|
||||
| In Vivo Model | Cervical cancer CDX model | ||||
| In Vitro Model | Skin squamous cell carcinoma | A431 cells | CVCL_0037 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 40) | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 6mg/kg Q4D 4.
Click to Show/Hide
|
||||
| In Vivo Model | Cervical cancer CDX model | ||||
| In Vitro Model | Skin squamous cell carcinoma | A431 cells | CVCL_0037 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 40) | Low 5T4 expression (5T4+) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ASN004 was studied in a tumor xenograft model derived from the A431 (human cervical epidermoid,5T4+; 88, 000 binding sites per cell) tumor cell line. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 10 mg/kg single dose.
Click to Show/Hide
|
||||
| In Vivo Model | Cervical cancer CDX model | ||||
| In Vitro Model | Skin squamous cell carcinoma | A431 cells | CVCL_0037 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 70) | High 5T4 expression (5T4+++) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 1 mg/kg Q4D 4.
|
||||
| In Vivo Model | Breast cancer CDX model | ||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells (5T4 overexpression) | CVCL_0062 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 70) | High 5T4 expression (5T4+++) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 3 mg/kg Q4D 4.
|
||||
| In Vivo Model | Breast cancer CDX model | ||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells (5T4 overexpression) | CVCL_0062 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 70) | High 5T4 expression (5T4+++) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. Subcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 6mg/kg Q4D 4.
|
||||
| In Vivo Model | Breast cancer CDX model | ||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells (5T4 overexpression) | CVCL_0062 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 70) | High 5T4 expression (5T4+++) | ||
| Method Description |
ASN004 was evaluated for efficacy in human tumor mouse xenograft models,derived from four different human tumor cell types,having a wide range of 5T4 expression levels. ubcutaneous tumor xenografts were developed in nude mice with established mean tumor volumes of 150 mm3. The dose of ASN004 was 10 mg/kg single dose.
|
||||
| In Vivo Model | Breast cancer CDX model | ||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells (5T4 overexpression) | CVCL_0062 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.07 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.09 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.09 nM
|
High 5T4 expression (5T4+++) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Bladder squamous cell carcinoma | SCaBER cells | CVCL_3599 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.12 nM
|
Moderate 5T4 expression (5T4++) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Bladder carcinoma | 5637 cells | CVCL_0126 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.12 nM
|
High 5T4 expression (5T4+++) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Amelanotic melanoma | A-375 cells | CVCL_0132 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.15 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.17 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Prostate carcinoma | DU145 cells | CVCL_0105 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.18 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Endocervical adenocarcinoma | HeLa cells | CVCL_0030 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.23 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.25 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Lung adenocarcinoma | A-549 cells | CVCL_0023 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.26 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Skin squamous cell carcinoma | A431 cells | CVCL_0037 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.31 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Bladder carcinoma | SW780 cells | CVCL_1728 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.34 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Glioblastoma | U-87MG cells | CVCL_0022 | ||
| Experiment 14 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.42 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Prostate carcinoma | PC-3 cells | CVCL_0035 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.42 nM
|
High 5T4 expression (5T4+++) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells (5T4 overexpression) | CVCL_0062 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.44 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Gestational choriocarcinoma | JEG-3 cells | CVCL_0363 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.56 nM
|
Moderate 5T4 expression (5T4++) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.57 nM
|
Negative 5T4 expression (5T4-) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Colon cancer | HT29 cells | CVCL_A8EZ | ||
| Experiment 19 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.62 nM
|
Negative 5T4 expression (5T4-) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 20 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.66 nM
|
Moderate 5T4 expression (5T4++) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Bladder carcinoma | TCCSUP cells | CVCL_1738 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.76 nM
|
Moderate 5T4 expression (5T4++) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Recurrent bladder carcinoma | HT-1197 cells | CVCL_1291 | ||
| Experiment 22 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.78 nM
|
Negative 5T4 expression (5T4-) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Bladder carcinoma | RT-4 cells | CVCL_0036 | ||
| Experiment 23 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.93 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Bladder carcinoma | T24 cells | CVCL_0554 | ||
| Experiment 24 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.95 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1975 cells | CVCL_1511 | ||
| Experiment 25 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.03 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1937 cells | CVCL_0290 | ||
| Experiment 26 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.05 nM
|
Low 5T4 expression (5T4+) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H1299 cells | CVCL_0060 | ||
| Experiment 27 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.06 nM
|
High 5T4 expression (5T4+++) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Bladder carcinoma | HT-1376 cells | CVCL_1292 | ||
| Experiment 28 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.34 nM
|
Negative 5T4 expression (5T4-) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Lung small cell carcinoma | DMS 114 cells | CVCL_1174 | ||
| Experiment 29 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.53 nM
|
Negative 5T4 expression (5T4-) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Bladder carcinoma | UM-UC-3 cells | CVCL_1783 | ||
| Experiment 30 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
4.28 nM
|
Moderate 5T4 expression (5T4++) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Bladder carcinoma | J82 cells | CVCL_0359 | ||
| Experiment 31 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
9.01 nM
|
Moderate 5T4 expression (5T4++) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Hepatoblastoma | Hep-G2 cells | CVCL_0027 | ||
| Experiment 32 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
9.03 nM
|
Moderate 5T4 expression (5T4++) | ||
| Method Description |
The cytotoxic effect of ASN004 was assessed in cell viability assays for a diverse panel of human solid tumor cell lines representing bladder,breast,cervical,colon,gastric,glioblastoma,liver,lung,melanoma,placenta,and prostate cancers.
|
||||
| In Vitro Model | Prostate carcinoma | LNCaP cells | CVCL_0395 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.